Jennifer J. Bradway
Known title: SVP & CORPORATE CONTROLLERCIK: 0001902394
Associated companies
Transaction History
| ECL | ▲ Buy | Option Exercise | 6,457 | — | 8/3/2026 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 2,944 | $821K | 8/3/2026 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 596 | $181K | 2/18/2026 | View on chart |
| ECL | ▲ Buy | Grant | 1,948 | $0 | 2/18/2026 | View on chart |
| ECL | ▲ Buy | Option Exercise | 950 | $130K | 2/13/2026 | View on chart |
| ECL | ▼ Sell | Open Market | 613 | $185K | 2/13/2026 | View on chart |
| ECL | ▲ Buy | Option Exercise | 993 | $117K | 8/13/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 807 | $225K | 8/13/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,057 | $126K | 2/25/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 856 | $229K | 2/25/2025 | View on chart |
| ECL | ▲ Buy | Grant | 608 | $0 | 2/19/2025 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 205 | $54K | 2/19/2025 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 56 | $12K | 2/25/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 183 | — | 2/25/2024 | View on chart |
| ECL | ▲ Buy | Grant | 496 | $0 | 2/21/2024 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 151 | $33K | 2/21/2024 | View on chart |
| ECL | ▼ Sell | Open Market | 944 | $204K | 2/15/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,122 | $121K | 2/15/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,489 | $0 | 12/3/2023 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 456 | $88K | 12/3/2023 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 165 | $26K | 3/1/2023 | View on chart |
| ECL | ▲ Buy | Grant | 458 | $0 | 2/22/2023 | View on chart |
| ECL | ▲ Buy | Grant | 326 | $0 | 2/23/2022 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 118 | $21K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength
Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength. Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.